Navigation Links
Trillium Strengthens its Board of Directors

TORONTO, Nov. 5 /PRNewswire/ - Trillium Therapeutics Inc., a privately held biopharmaceutical company, announced today that industry veterans Dr. Michael Berendt and Dr. John Dietrich have joined its Board as independent directors. Trillium Chairman Dr. Michael Moore commented: "It is a great pleasure to welcome these two experienced biotech executives to the Board where they will enhance our capabilities in strategic planning and product development. Their appointments are commensurate with completion of an internal financing round of $12 million and the entry into clinical development of Trillium's lead product, TTI-1612."

About Dr. Michael Berendt: Dr. Berendt is the President and CEO of Aegera Therapeutics. Prior to joining Aegera, he served as managing director of Research Corporation Technologies (RCT), a US-based technology investment and management company, and AEA Investors Inc., where focusing on growth equity investments in life sciences companies. Previously Dr. Berendt was Senior Vice President of Research for the Pharmaceutical Division of Bayer Corporation. He is currently a director of Waters Corporation and has served on the board of directors of numerous other life sciences companies. Dr. Berendt received a doctoral degree in medical microbiology and immunology from Hahnemann University.

About Dr. John Dietrich: Dr. Dietrich joined Ventrus Biosciences in April 2007, where he currently serves as Vice President, Clinical Operations. From 2000 to 2007, Dr. Dietrich was Vice President of Research and Development at VIVUS, Inc, prior to which he was Vice President of Research and Development at Cellegy Pharmaceuticals. Dr. Dietrich served as Senior Vice President of Research and Development at Allelix Biopharmaceuticals between 1991 and 1999. In this position, he was responsible for all aspects of drug discovery and development. Before joining Allelix, he held management positions at Chemex and Revlon Health Care. Dr. Dietrich received his PhD in pharmacology from the University of North Carolina at Chapel Hill.

About Trillium: Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as cancer. The company's lead program, a recombinant heparin-binding epidermal growth factor-like growth factor (HB-EGF), is being developed for the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. IND filing on the lead product, TTI-1612, was submitted to the FDA in October 2008. In addition, Trillium has two preclinical programs targeting the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases. The company has a broad network of external academic and industry R&D collaborations, including several license agreements with major US biotechnology companies. To date the Company has raised approximately $25 million in investment capital through Vengrowth Private Equity Partners, Canadian Medical Discoveries Fund (CMDF) and BDC Venture Capital.

SOURCE Trillium Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
2. Medpace Strengthens Presence in Central Europe
3. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
4. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
5. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
6. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
7. Anavex strengthens Board of Directors
8. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. Strengthens Local Market Candidate Reach Through Acquisition
11. Strengthens Local Market Candidate Reach Through Acquisition
Post Your Comments:
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... maintain healthy metabolism. But unless it is bound to proteins, copper is also ... Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study ...
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has ... Prix, to represent the First–Person View (FPV) racing community. , FPV racing has exploded ... of racing and several new model aviation pilots have joined the community because of ...
Breaking Biology Technology:
(Date:10/29/2015)... YORK , Oct. 29, 2015 ... technology, announced a partnership with 2XU, a global ... to deliver a smart hat with advanced bio-sensing ... and other athletes to monitor key biometrics to ... the strategic partnership, the two companies will bring together ...
(Date:10/27/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... has adopted the Synaptics ® ClearPad ® ... its newest flagship smartphones, the Nexus 5X by LG ... --> --> Synaptics works closely ... collaboration in the joint development of next generation technologies. ...
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):